Human monoclonal antibodies

  title={Human monoclonal antibodies},
  author={Susan P. C. Cole and Barbara G Campling and Tsehay Atlaw and Danuta Kozbor and John C. Roder},
  journal={Molecular and Cellular Biochemistry},
SummaryThe technology for the production of murine monoclonal antibodies has been refined enormously since its introduction in 1975. However, the technology for generating human monoclonal antibodies has only recently come into its own. In this review, three currently available approaches to the production of human monoclonal antibodies are described. These include the hybridoma technique, based on the fusion of antibody-producing human B lymphocytes with either mouse or human myeloma or… 

Human monoclonal antibodies neutralizing human cytomegalovirus.

Results suggest that human MAbs may provide a new means of passive immunization against CMV infection in humans.

Tumour-associated antigens of mammary carcinomas recognized by human monoclonal antibody 1G12

Results show that human mAb 1G12 may be useful for the analysis of tumour-associated antigen of mammary carcinoma patients.

Advances in the production of human monoclonal antibodies

This review serves as an introduction to the immortalization of antigen-specific human B cell and hybridoma technologies, phage display platform, the use of transgenic mice, and the generation of monoclonal antibodies from single B cells.

Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy

An overview of phage display derived recombinant antibodies against bacterial, viral and eukaryotic pathogens, as well as microbial toxins, intended for diagnostic and therapeutic applications are presented.

Human monoclonal autoantibodies to characterize platelet antigens in immune-mediated thrombocytopenia

The use of human monoclonal autoantibodies are described to characterize an activation specific antigen on GPIIIa and an autoantigen on the GPIb complex to determine whether these autoantibia emerge from a pool of naturally occurring antibodies to activation or senescence antigens, or are triggered by environmental agents such as bacteria or virus.

Development of whole-porcine monoclonal antibodies with potent neutralization activity against classical swine fever virus (CSFV) from single B cells

The results suggest that the results not only provide a method for efficiently obtaining mAbs against CSFV but also offer promising mAb candidates for development of antibody-based diagnostic and antiviral agents, and it is demonstrated that these two mAbs can be used as novel reagents for detecting virus infection.

Evaluation of new lentiviral vector pseudotypes for gene transfer into hematopoietic cells

Adapt vectors for gene transfer at each stage of differentiation from CD34+ cells to thymocytes and mature T cells are proposed to allow some new clinical protocols in gene therapy with a co-transplantation of genetically modified stem cells and their differentiated T progenitors in order to reduce the aplasia stage induced by current transplantation protocols.

Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids.

  • G. S. Hamilton
  • Biology, Chemistry
    Biologicals : journal of the International Association of Biological Standardization
  • 2015

Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosis and treatment (1993-2013).

Evidence obtained suggests promising potential of monoclonal antibodies and nuclear medicine, with immunoscintigraphy and radioimmunotherapy techniques providing alternatives for cancer diagnosis and treatment in Cuba.

Improving scFv stability through framework engineering

This thesis explored the following strategies to increase scFv stability and designed a new selection/screening strategy using phage display and yeast two-hybrid assays to identify complementarity determining regions on scFvs that increased intracellular stability.



Human monoclonal antibody against Forssman antigen.

Findings point to the potential use of human-mouse hybrid cells as a source of human monoclonal antibodies for therapeutic and diagnostic purposes.

Production of human hybridomas secreting antibodies to measles virus

A hypoxanthine phosphoribosyl transferase (HPRT)-deficient human B-cell line derived from a patient suffering from multiple myeloma with peripheral lymphocytes obtained from a patients with subacute sclerosing panencephalitis were found to secrete human IgM specific for measles virus nucleocapsids.

Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes

The continuous production in vitro of a monoclonal IgM anti-IgG antibody (rheumatoid factor, r.f.) by a lymphoblastoid cell line established from a patient with rheumatoids arthritis is demonstrated.

Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells

The study demonstrates that some patients with AML generate an immune response against their autologous malignant cells, and that the antigenic determinant in the case of aml-18 is also expressed specifically on leukemic cells from other patients.

Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.

  • L. OlssonH. Kaplan
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1980
It is reported the establishment of human-human hybridomas producing monoclonal antibody of predefined antigenic specificity from patients with untreated Hodgkin's disease who had been previously sensitized to the chemical allergen 2,4-dinitrochlorobenzne.

Determination of the optimal human cell lines for development of human hybridomas.

Among the lines tested, UC729-6 and HF2 appeared optimal for pursuing further studies with human-human hybridomas, and although only a small percentage of hybrids were produced with HMy2, a very high percentage secreted immunoglobulin, so that this line also warrants further investigation to improve the efficiency of hybrid formation.

Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.

It is demonstrated that stable clones of human-mouse hybridomas can be generated by using lymph nodes of mastectomy patients and that clones can be selected which synthesize human monoclonal antibodies reactive with human mammary carcinoma cells.